NCT00670943

Effect of Abrupt Plavix® Discontinuation on Platelet Function

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 52 (estimated)
• Sponsor: Université de Montréal · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The well established importance of regular administration of antiplatelet drugs stands on firm grounds, as large meta-analyses have shown these therapies to significantly reduce the risk of death. Plavix® (clopidogrel) is widely used following coronary angioplasty, to reduce the risk of periprocedural thrombotic complications, for up to one year. As the current recommendations suggest clopidogrel use for no longer than one year, the drug is normally discontinued within that period. In the limited state of knowledge on antiplatelet drug withdrawal, an early sound of alarm has risen from early thromboembolic complications reported after the interruption of antiplatelet treatment used in prevention of ischemic vascular disease. Although little information is available, discontinuation of thienopyridines has been associated with increased thromboembolic complications, mainly acute stent thrombosis. These complications may signal a platelet sensitization effect to aggregating stimuli by antiplatelet drugs taken chronically. The current study aims to evaluate the impact of clopidogrel discontinuation on platelet function, in order to shed light on underlying mechanisms leading to increased risk of acute thrombo-occlusive events.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
OTHER	Platelet function testing

Timeline

• Start date: 2008-01-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-05-02
• Last updated: 2009-03-25

Locations

1 site across 1 country: Canada